Form 4: CorMedix Director Sells 30,000 Shares Under 10b5-1 Plan

CorMedix Inc. Director Janet Dillione sold 30,000 shares of common stock at a weighted average price of $11.42 on November 14, 2025, pursuant to a Rule 10b5-1 plan.

Summary

• Janet Dillione, a Director of CorMedix Inc. (CRMD), reported the sale of 30,000 shares of common stock.
• The transaction occurred on November 14, 2025.
• The shares were sold at a weighted average price of $11.42 per share, with individual trades ranging from $11.41 to $11.44.
• The sale was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following this transaction, Janet Dillione beneficially owns 48,473 shares of CorMedix Inc. common stock.

Sentiment

Score: 5

Explanation: A director's sale of shares is generally viewed neutrally to slightly negatively. However, the disclosure that the transaction was made pursuant to a Rule 10b5-1 plan mitigates potential negative interpretations, as it indicates a pre-scheduled sale not based on immediate, non-public information.

Negatives

• A director's sale of 30,000 shares, even under a Rule 10b5-1 plan, reduces their direct ownership in the company.

Stakeholder Impact

• Shareholders may observe the reduction in a director's direct holdings, though the 10b5-1 plan context suggests the sale is for personal financial planning rather than a reaction to new company-specific information.

Key Dates

Recommendation

A director's sale of 30,000 shares, while notable, was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily indicative of a change in fundamental outlook. Investors should monitor broader insider activity and company performance rather than reacting solely to this single transaction.

Keywords

CorMedix, CRMD, Insider Trading, Form 4, Stock Sale, Janet Dillione, Director, 10b5-1 Plan